4th Microbiome Movement - Drug Development Summit

Memo

The study of the human microbiome remains one of the most exciting frontiers in modern medicine, that, if targeted correctly, has the potential to benefit millions of patients suffering from numerous diseases. However, the potential for effective disease treatment through the microbiome is matched by the unique challenges in developing them. The 4th Microbiome Movement – Drug Development Summit returns to help cutting-edge pharmaceutical and academic researchers pursue the causal role of the human microbiome in disease to help deliver a new generation of targeted therapeutics, biomarker and diagnostics to patients that demonstrate consistent clinical outcomes and mechanisms of action.So whether you’re part of a microbiome-focused biotech, a pharmaceutical organization assessing this exciting field, or an academic researcher with breakthrough findings, join the Microbiome Movement as we explore the global advances in translational microbiome research, and meet like-minded peers who are continuing to understand the causal and therapeutic potential of the human microbiome.Hear from thought leaders and microbiome pioneers such as: Seres Therapeutics, Vedanta Biosciences, CoreBiome, Janssen Pharmaceuticals, Novome Biotechnologies, Microbiotica and 50+ more. Visit the website to see the complete speaker faculty. Early booking and group discount rates apply. Visit the website to see all registration packages, discounts and eligibility criteria. URLs:Tickets: https://go.evvnt.com/354252-2?pid=5569Brochure: https://go.evvnt.com/354252-3?pid=5569PriceDrug Developer: Pharma & Biotech Standard Rate - Full Access: USD 4198.0Drug Developer: Pharma & Biotech Standard Rate - Conference Only: USD 2799.0Solution & Service Provider Standard Rate - Full Access: USD 5198.0Solution & Service Provider Standard Rate - Conference Only: USD 3799.0Artists / Speakers: Bernat Olle, CEO, Vedanta Biosciences, Dan Knights, CEO, CoreBiome, Esi Lamouse-Smith, Director, Janssen Pharmaceuticals, Liz Shepherd, Co-Founder, Novome Biotechnologies, Matthew Henn, EVP Microbiome R&D, Seres Therapeutics, Mike Romanos, CEO, Microbiotica, Mark Smith, CEO, Finch Therapeutics Group, Daniel van der Lelie, Chief Scientific Officer, Gusto Global, Julius Goepp, CEO, Scaled Microbiomics, Gregory Lambert, CEO, TargEDys, Colleen Cutcliffe, Co-Founder & CEO, Whole BiomeWednesday June 26, 2019 at 8:30 am (ends Friday June 28, 2019 at 5:00 pm)Venue detailsRevere Hotel Boston Common200 Stuart Street, Boston 02116, United States